Phase II DESTINY-CRC01: Trastuzumab Deruxtecan in Patients With HER2-Expressing Metastatic Colorectal Cancer

May 29-31, 2020; Online at meetings.asco.org/am
In patients with previously treated HER2+ metastatic CRC, T-DXd associated with a response rate of 45% and durable responses.
Format: Microsoft PowerPoint (.ppt)
File Size: 256 KB
Released: June 1, 2020

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

Gain key clinical insights quickly with this short slideset from Clinical Care Options (CCO) on targeted and immunotherapies for HCC and BTCs

Richard S. Finn, MD Amit G. Singal, MD, MS Mark Yarchoan, MD Released: November 18, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

In slides from Clinical Care Options (CCO), experts provide insights on the use of targeted therapies for advanced biliary tract cancer

Mark Yarchoan, MD Released: November 12, 2021

In slides from Clinical Care Options (CCO), experts discuss emerging data surrounding use of immune checkpoint inhibitors for early HCC

Amit G. Singal, MD, MS Released: November 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue